This analysis of antiosteoporosis therapy shows that 75% of patients have inadequate drug coverage and that adherence is strongly associated with age and administration regimen.
Luisa De Fendi, BSc
Advertisement
Articles by Luisa De Fendi, BSc
Advertisement
Latest Updated Articles
- Assessment and Potential Determinants of Compliance and Persistence to Antiosteoporosis Therapy in Italy
Published: May 19th 2014 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
4
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
5
